Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.53 |
| ▸ | AR | P10275 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 4/20 | 0.49 |
| ▸ | FNTA | P49354 | 1/20 | 0.47 |
| ▸ | FNTB | P49356 | 1/20 | 0.47 |
| ▸ | CXCL12 | P48061 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.47 |
| ▸ | GUSB | P08236 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498937 | 0.86 | MEN1 (0.50) | ABCG2MAPTHTT | |
| SCHEMBL499271 | 0.82 | CYP1A2 (0.48) | MAPT | |
| SCHEMBL498929 | 0.79 | ABCB1 (0.55) | MAOBABCG2MAOACXCL12MAPT | |
| SCHEMBL498878 | 0.77 | ABCG2 (0.49) | MAOBABCG2ARCXCL12MAPT | |
| SCHEMBL498938 | 0.75 | FNTA (0.39) | MAOBMAOAFNTAFNTBMAPT | |
| SCHEMBL6717914 | 0.74 | ABCG2 (0.68) | MAOBABCG2ARMAOAFNTA | |
| SCHEMBL25340711 | 0.73 | ABCB1 (0.76) | MAOBABCG2MAOACXCL12MAPT | |
| SCHEMBL5604388 | 0.73 | MAOB (0.52) | MAOBABCG2MAOACXCL12MAPT | |
| SCHEMBL25953136 | 0.73 | ABCB1 (0.64) | MAOBABCG2MAOACXCL12MAPT | |
| SCHEMBL25952383 | 0.73 | ABCB1 (0.76) | MAOBABCG2MAOACXCL12MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058308-B2 | Substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2011-11-15 | — | — | US | claimed |
| US-7566737-B2 | Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2009-07-28 | — | — | US | claimed |
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2007-02-08 | — | — | US | claimed |
| EP-1525177-A1 | SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES AND PREPARATION AND USES THEREOF | Genfit (FR) | 2005-04-27 | — | — | EP | claimed |
| EP-1519908-A2 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | Genfit (FR) | 2005-04-06 | — | — | EP | claimed |
| WO-2004005243-A2 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES | GENFIT (FR) | 2004-01-15 | — | — | WO | claimed |
| WO-2004005233-A1 | SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES AND PREPARATION AND USES THEREOF | GENFIT (FR) | 2004-01-15 | — | — | WO | claimed |
| US-8461212-B2 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2013-06-11 | — | — | US | disclosed |
| US-20120129932-A1 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2012-05-24 | — | — | US | disclosed |
| US-8106097-B2 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2012-01-31 | — | — | US | disclosed |
| US-8058308-B2 | Substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2011-11-15 | — | — | US | disclosed |
| US-20110190515-A1 | SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2011-08-04 | — | — | US | disclosed |
| US-7943661-B2 | Antiischemic agents; for example 1-[2-hydroxy-4-chlorophenyl]-3-[4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one; display peroxisome proliferator activated receptor (PPAR) activator, antioxidant and antiinflammatory properties | GENFIT (FR) | 2011-05-17 | — | — | US | disclosed |
| US-20050176808-A1 | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof | GENFIT (FR) | 2005-08-11 | — | — | US | disclosed |
| US-20050171149-A1 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2005-08-04 | — | — | US | disclosed |
| EP-1525177-A1 | SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES AND PREPARATION AND USES THEREOF | Genfit (FR) | 2005-04-27 | — | — | EP | disclosed |
| EP-1519908-A2 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | Genfit (FR) | 2005-04-06 | — | — | EP | disclosed |
| WO-2005005369-A1 | PREPARATION OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES | GENFIT (FR) | 2005-01-20 | — | — | WO | disclosed |
| WO-2004005243-A2 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES | GENFIT (FR) | 2004-01-15 | — | — | WO | disclosed |
| WO-2004005233-A1 | SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES AND PREPARATION AND USES THEREOF | GENFIT (FR) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | PSEN1, BACE1, PSEN2 | MAOB 2058/4885ABCG2 2957/4885AR 1082/4885 |
| US-20110190515-A1 | SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | PGF, PTGS1, PTGES3 | MAOB 705/4885ABCG2 864/4885AR 4390/4885 |
| US-20120129932-A1 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | BRCA1, COL1A1, APOL1 | MAOB 840/4885ABCG2 4139/4885AR 364/4885 |
| US-20050176808-A1 | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof | PGF, PTGS1, PTGES3 | MAOB 692/4885ABCG2 828/4885AR 4331/4885 |
| US-20050171149-A1 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | BRCA1, LOXL1, APOL1 | MAOB 845/4885ABCG2 3960/4885AR 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.